AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound comprising the formula:

(I)



wherein:

R_1 is a polymeric residue;

Y_1 is O, S or NR_4;

M is O, S or NR_5;

E_1 is



E_{2-4} are independently H, E_1 or



(a) is zero or one;

(m) is zero or a positive integer;

(n) and (p) are independently 0 or a positive integer;

Y_{2-3} are independently O, S or NR_{10};

R_{2-10} are independently selected from the group consisting of hydrogen, C_{1-6} alkyls, C_{3-12} branched alkyls, C_{3-8} cycloalkyls, C_{1-6} substituted alkyls, C_{3-8} substituted cycloalkyls, aryls, substituted aryls, aralkyls, C_{1-6} heteroalkyls, substituted C_{1-6} hetero-alkyls, C_{1-6} alkoxy, phenoxy and C_{1-6} heteroalkoxy;

D_1 and D_2 are independently ~~OH;~~

(IV)



(V)



~~or a terminal branching group;~~

wherein

(v) and (t) are independently 0 or a positive integer up to about 6;

(q) is zero or a positive integer;

L_1 and L_2 are independently selected bifunctional linkers;

Y_{4-7} are independently selected from the group consisting of O, S and NR_{14};

R_{11-14} are independently selected from the group consisting of hydrogen, C_{1-6} alkyls, C_{3-12} branched alkyls, C_{3-8} cycloalkyls, C_{1-6} substituted alkyls, C_{3-8} substituted cycloalkyls, aryls, substituted aryls, aralkyls, C_{1-6} heteroalkyls, substituted C_{1-6} heteroalkyls, C_{1-6} alkoxy, phenoxy and C_{1-6} heteroalkoxy ~~heteroakoxy~~;

Ar is a moiety which when included in Formula (I) forms a multi-substituted aromatic hydrocarbon or a multi-substituted heterocyclic group;

B_1 and B_2 are independently selected from the group consisting of leaving groups, OH, residues of hydroxyl-containing moieties or amine-containing moieties; or

a terminal branching group of the formula



wherein

E_{35} is



$E_{36\text{-}38}$ are independently H, E_{35} or



D'_1 is

(IV)



(V)



or



D'$_2$ is OH,





or



wherein

E_{45} is



E_{46-48} are independently H, E_{45} or



wherein

D''_1 is

(IV)



or

(V)



D''$_2$ is OH,

(IV)



or

(V)



provided that E_{2-4} are not all H ~~and~~

~~D_1 and D_2 are both not OH.~~

2. (Original) The compound of claim 1, wherein R_1 further comprises a capping group A, selected from the group consisting of hydrogen, NH_2, OH, CO_2H, C_{1-6} moieties and



3. (Original) A compound of claim 2, comprising the formula:



4. (Cancelled)

5. (Previously Presented) The compound of claim 3, wherein Y_1 is O.

6. (Original) The compound of claim 1, wherein R_1 comprises a polyalkylene oxide residue.

7. (Original) The compound of claim 6, wherein R_1 comprises a polyethylene glycol residue.

8. (Original) The compound of claim 3, wherein R_1 comprises a polyethylene glycol residue.

9. (Original) The compound of claim 6, wherein R_1 is selected from the group consisting of

$-C(=Y_8)-(CH_2)_f-O-(CH_2CH_2O)_x-A$, $-C(=Y_8)-Y_9-(CH_2)_f-O-(CH_2CH_2O)_x-A$,

$-C(=Y_8)-NR_{20}-(CH_2)_f-O-(CH_2CH_2O)_x-A$, $-(CR_{21}R_{22})_e-O-(CH_2)_f-O-(CH_2CH_2O)_x-A$,

$-NR_{20}-(CH_2)_f-O-(CH_2CH_2O)_x-A$, $-C(=Y_8)-(CH_2)_f-O-(CH_2CH_2O)_x-(CH_2)_f-C(=Y_8)-$,

$-C(=Y_8)-Y_9-(CH_2)_f-O-(CH_2CH_2O)_x-(CH_2)_f-Y_9-C(=Y_8)-$,

$-C(=Y_8)-NR_{20}-(CH_2)_f-O-(CH_2CH_2O)_x-(CH_2)_f-NR_{20}-C(=Y_8)-$,

$-(CR_{21}R_{22})_e-O-(CH_2)_f-O-(CH_2CH_2O)_x-(CH_2)_f-O-(CR_{21}R_{22})_e-$, and

$-NR_{20}-(CH_2)_f-O-(CH_2CH_2O)_x-(CH_2)_f-NR_{20}-$

wherein:

Y_8 and Y_9 are independently O, S or NR_{20};

x is the degree of polymerization;

R_{20}, R_{21} and R_{22} are independently selected from among H, C_{1-6} alkyls, C_{3-12} branched alkyls, C_{3-8} cycloalkyls, C_{1-6} substituted alkyls, C_{3-8} substituted cycloalkyls, aryls, substituted aryls, aralkyls,

C_{1-6} heteroalkyls, substituted C_{1-6} heteroalkyls, C_{1-6} alkoxy, phenoxy and C_{1-6} heteroalkoxy;

e and *f* are independently zero, one or two; and

A is a capping group.

10. (Original) The compound of claim 9, wherein R_1 comprises $-O-(CH_2CH_2O)_x$ and x is a positive integer so that the weight average molecular weight is at least about 20,000.

11. (Original) The compound of claim 3, wherein R_1 has a weight average molecular weight of from about 20,000 to about 100,000.

12. (Original) The compound of claim 3, wherein R_1 has a weight average molecular weight of from about 25,000 to about 60,000.

13. (Original) A compound of claim 3, comprising the formula



14. (Original) The compound of claim 13, wherein D_1 is



15. (Original) The compound of claim 13, wherein D_1 is



16. (Original) The compound of claim 1, wherein L_1 is $(CH_2CH_2O)_2$.

17. (Original) The compound of claim 1, wherein L_2 is selected from the group consisting of $-CH_2-$, $-CH(CH_3)-$, $-CH_2C(O)NHCH(CH_3)-$, $-(CH_2)_2-$, $-CH_2C(O)NHCH_2-$, $-(CH_2)_2-NH-$, $-(CH_2)_2-NH-C(O)(CH_2)_2NH-$ and $-CH_2C(O)NHCH(CH_2CH(CH_3)_2)-$.

18. (Original) A compound of claim 1, selected from the group consisting of:











and



wherein R_1 is a PEG residue and D is selected from the group comprising:



























and



where B is a residue of an amine or a hydroxyl- containing drug.

19. (Original) A compound of claim 18, wherein B is a residue of a member of the group consisting of: daunorubicin, doxorubicin; *p*-aminoaniline mustard, melphalan, Ara-C (cytosine arabinoside), leucine-Ara-C, and gemcitabine.

20. (Original) A method of treatment, comprising administering to a mammal in need of such treatment an effective amount of a compound of claim 1, wherein D_1 is a residue of a biologically active moiety.

21. (Original) A method of treatment, comprising administering to a mammal in need of such treatment an effective amount of a compound of claim 18.

22. (Previously Presented) A method of preparing a polymer conjugate, comprising:

reacting a compound of the formula (VIII):



(VIII)

wherein

(v) and (t) are independently 0 or a positive integer up to about 6;

L_1 and L_2 are independently selected bifunctional linkers;

Y_{4-7} are independently selected from the group consisting of O, S and NR_{14};

R_{11-14} are independently selected from the group consisting of hydrogen, C_{1-6} alkyls, C_{3-12} branched alkyls, C_{3-8} cycloalkyls, C_{1-6} substituted alkyls, C_{3-8} substituted cycloalkyls, aryls, substituted aryls, aralkyls, C_{1-6} heteroalkyls, substituted C_{1-6} heteroalkyls, C_{1-6} alkoxy, phenoxy and C_{1-6} heteroalkoxy;

Ar is a moiety which when included in Formula (I) forms a multi-substituted aromatic hydrocarbon or a multi-substituted heterocyclic group; and

B'_1 is a residue of a hydroxyl- or an amine-containing moiety;

with a compound of the formula (IX):

(IX)



wherein

E_5 is



E_{6-8} are independently H, E_5 or



wherein

D_3 and D_4 are independently OH, a leaving group which is capable of reacting with an unprotected amine or hydroxyl or a terminal branching group;

R_1 is a polymeric residue;

Y_1 is O, S or NR_4;

M is O, S or NR_5;

(n) and (p) are independently 0 or a positive integer;

Y_{2-3} are independently O, S or NR_{10}; and

R_{2-10} are independently selected from the group consisting of hydrogen, C_{1-6} alkyls, C_{3-12} branched alkyls, C_{3-8} cycloalkyls, C_{1-6} substituted alkyls, C_{3-8} substituted cycloalkyls, aryls, substituted aryls, aralkyls, C_{1-6} heteroalkyls, substituted C_{1-6} hetero-alkyls, C_{1-6} alkoxy, phenoxy and C_{1-6} heteroalkoxy;

provided that E_{6-8} are not all H;

and D_3 and D_4 are not both OH;

under conditions sufficient to cause a polymeric conjugate to be formed.